Could Nanotechnology Solve CBD’s Absorption Problem?

Cannabidiol (CBD) has become one of the most widely studied cannabinoids, with researchers investigating its potential across a range of biomedical applications. Yet one of the biggest obstacles to turning CBD into a more predictable therapeutic ingredient has little to do with the molecule itself. The problem is delivery.

CBD has several physicochemical characteristics that make consistent formulation difficult. It has very low water solubility, undergoes substantial first-pass metabolism after oral administration, and typically has an oral bioavailability of only about 6% to 20%. In other words, getting a controlled amount of CBD into the body, and ultimately to the tissue where it is needed, is considerably more complicated than simply taking a dose.

Now, researchers are exploring whether nanotechnology could change that equation. A 2026 review¹ published in Biomedicine & Pharmacotherapy examines a new generation of hybrid nanosystems for CBD, highlighting how combining different delivery technologies could potentially protect CBD, improve its absorption, control its release, and even direct it toward specific tissues. The findings are intriguing, but they also come with an important caveat, as this technology remains firmly in the preclinical stage. Let’s dive into the research and how this could change the future of cannabinoid medicine.

Why CBD Absorption Is So Difficult

CBD is lipophilic, meaning it does not readily dissolve in water. The review estimates its aqueous solubility at approximately 0.01 mg/mL, creating an immediate formulation challenge. Oral CBD faces another hurdle once it is absorbed. A substantial portion can be metabolized during its first pass through the liver, reducing the amount that ultimately reaches systemic circulation. This combination can contribute to inconsistent exposure and makes it difficult to predict exactly how much CBD will reach a particular tissue.

Researchers have therefore investigated delivery systems such as liposomes, polymeric nanoparticles, and inorganic nanoparticles. These platforms can encapsulate CBD and potentially improve its stability, solubility, absorption, and release characteristics. However, conventional nanosystems are not perfect either. Some can suffer from burst release, where much of the encapsulated compound is released too quickly, while others can have stability problems during storage or use. That is where the “hybrid” concept becomes particularly interesting.

What Makes a CBD Nanosystem Hybrid?

Rather than relying on a single type of nanoparticle, hybrid systems combine different materials or delivery mechanisms to take advantage of their individual strengths. The goal is not simply to make CBD smaller. Instead, researchers are attempting to create a delivery platform that can protect CBD from degradation, hold a greater amount of the compound, remain stable, and release it in a controlled manner.

According to the 2026 review, hybrid systems could potentially provide higher loading efficiency, improved stability, reduced premature release, and better bioavailability than some single-platform approaches. They may also be engineered for site-specific delivery, including oral, transdermal, and central nervous system targeted applications.

That could represent a significant shift in how CBD is formulated. Instead of asking simply, “How much CBD is in this product?” researchers could eventually ask a much more sophisticated question: How much CBD reaches the intended tissue, when does it get there, and how long does it remain available?

How Nanotechnology Could Improve CBD Delivery

One of the most promising possibilities is controlled release. A delivery system can potentially act as a protective carrier around CBD, limiting premature release and allowing the compound to become available over a longer period. This could be particularly valuable for localized treatments where maintaining exposure at a specific site matters.

Topical and transdermal delivery is another area attracting attention. Experimental CBD nanocarriers have demonstrated enhanced skin permeation in laboratory and ex vivo models. In one study, a nanoemulsion incorporated into a chitosan hydrogel produced greater cumulative CBD permeation and a higher steady-state flux across porcine ear skin than the nanoemulsion alone.

Other hybrid formulations have demonstrated sustained CBD release. A thermo-responsive hydrogel combining CBD, hyaluronic acid, and colloidal silver nanoparticles was designed to remain easy to apply before forming a more stable matrix at skin temperature. Laboratory testing showed that the hydrogel slowed and controlled CBD release compared with an unstructured formulation.

These approaches could eventually allow CBD to be delivered locally rather than relying entirely on systemic exposure.

An Ocular Study Offers a Closer Look

Perhaps one of the more striking examples involves the eye. Researchers developed an ocular formulation containing CBD and epigallocatechin-3-gallate, or EGCG, encapsulated in niosomes and incorporated into an ion-sensitive gel. The system was designed to remain on the ocular surface longer while providing sustained release. The formulation demonstrated high encapsulation efficiency and sustained release in laboratory testing.

However, the finding that may catch the most attention involved methicillin-resistant Staphylococcus aureus (MRSA). In an in vitro biofilm experiment, the CBD-EGCG formulation inhibited approximately 60% of MRSA biofilm formation at the tested concentration. Lower concentrations produced smaller effects. While this is an interesting result, it is critical to understand what it does and does not mean. The experiment did not demonstrate that a CBD eye treatment can treat an MRSA infection in humans. It demonstrated activity in a laboratory model using a specific formulation. Further research would be required to determine whether the finding translates into an effective and safe medical treatment.

Could CBD Become a More Precise Drug?

This is ultimately what makes hybrid nanotechnology so compelling. The technology could potentially transform CBD from a compound that is difficult to absorb consistently into a more precisely engineered pharmaceutical ingredient. A future formulation might be designed to protect CBD during digestion, improve absorption through the intestinal tract, bypass some metabolic limitations, release the compound gradually, or concentrate delivery at a particular tissue.

For topical applications, the objective could be different: to improve penetration through the skin while maintaining CBD at the desired location. For ocular applications, researchers may prioritize residence time and controlled release. And for neurological applications, the long-term goal could include delivery systems capable of directing CBD toward the central nervous system. The same molecule could therefore potentially have very different delivery strategies depending on the therapeutic target.

Why Nano-CBD Is Not Ready for Patients

The promise should not be confused with clinical proof. The research into CBD-loaded hybrid nanosystems remains predominantly preclinical. Laboratory experiments, ex vivo models, and animal studies can demonstrate that a formulation is technically capable of improving delivery, but they cannot establish that it is safe or effective in humans.

There are several hurdles that still remain. Researchers must determine whether these nanosystems can be manufactured consistently at commercial scale, remain stable throughout their shelf life, and behave predictably from one batch to another. Long-term safety also needs careful evaluation, particularly because nanoparticles introduce additional materials and biological interactions that conventional CBD formulations may not have.

Regulatory requirements could also be substantial. A delivery system designed to alter where, when, and how CBD enters the body would require rigorous characterization of pharmacokinetics, toxicity, manufacturing quality, and clinical performance.

Most importantly, no hybrid CBD delivery system has yet established clinical efficacy through human trials.

The Future May Be About Delivery

The next major advancement in CBD research may not involve discovering another potential effect of the molecule. It may involve figuring out how to deliver the molecule better. Hybrid nanosystems offer a fascinating possibility, as they can potentially protect CBD from degradation, improve absorption, reduce waste, control its release, and potentially guide it toward the tissue where it is needed. Early research suggests that the concept deserves serious investigation. However, the field still has a considerable distance to travel.

For now, nano-enabled CBD remains a promising preclinical technology rather than a proven clinical breakthrough. The most important question going forward will not simply be whether researchers can build a better CBD delivery system in the laboratory. It will be whether those systems can safely, consistently, and meaningfully improve CBD delivery in humans.

References:

^{1. Matheus Valentin Maia, Eryvaldo Sócrates Tabosa do Egito, Daniela Sachs, Franceline Reynaud, Anne Sapin-Minet, Daniel Cristian Ferreira Soares, Next-generation hybrid nanosystems for cannabidiol: From molecular challenges to site-specific preclinical applications, Biomedicine & Pharmacotherapy, Volume 203, 2026, 119877, ISSN 0753-3322, https://doi.org/10.1016/j.biopha.2026.119877}